Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Loss of Roundabout Guidance Receptor 2 (Robo2) in Podocytes Protects Adult Mice from Glomerular Injury by Maintaining Podocyte Foot Process Structure.

Pisarek-Horowitz A, Fan X, Kumar S, Rasouly HM, Sharma R, Chen H, Coser K, Bluette CT, Hirenallur-Shanthappa D, Anderson SR, Yang H, Beck LH Jr, Bonegio RG, Henderson JM, Berasi SP, Salant DJ, Lu W.

Am J Pathol. 2020 Mar 20. pii: S0002-9440(20)30024-9. doi: 10.1016/j.ajpath.2019.12.009. [Epub ahead of print]

PMID:
32220420
2.

Phospholipase A2 Receptor Antibody-Positive Pregnancy: A Case Report.

Sachdeva M, Beck LH Jr, Miller I, Bijol V, Fishbane S.

Am J Kidney Dis. 2020 Feb 21. pii: S0272-6386(19)31169-2. doi: 10.1053/j.ajkd.2019.11.011. [Epub ahead of print]

PMID:
32093980
3.

Refining Our Understanding of the PLA2R-Antibody Response in Primary Membranous Nephropathy: Looking Forward, Looking Back.

Beck LH Jr, Salant DJ.

J Am Soc Nephrol. 2020 Jan;31(1):8-11. doi: 10.1681/ASN.2019111195. Epub 2019 Dec 16. No abstract available.

PMID:
31871252
4.

Membranous nephropathy: diagnosis, treatment, and monitoring in the post-PLA2R era.

Safar-Boueri L, Piya A, Beck LH Jr, Ayalon R.

Pediatr Nephrol. 2019 Dec 6. doi: 10.1007/s00467-019-04425-1. [Epub ahead of print] Review.

PMID:
31811540
5.

Management of Membranous Nephropathy after MENTOR.

Trivin-Avillach C, Beck LH Jr.

Clin J Am Soc Nephrol. 2020 Mar 6;15(3):415-417. doi: 10.2215/CJN.10240819. Epub 2019 Nov 18. No abstract available.

PMID:
31740571
6.

Membranous Nephropathy Posttransplantation: An Update of the Pathophysiology and Management.

Leon J, Pérez-Sáez MJ, Batal I, Beck LH Jr, Rennke HG, Canaud G, Legendre C, Pascual J, Riella LV.

Transplantation. 2019 Oct;103(10):1990-2002. doi: 10.1097/TP.0000000000002758.

PMID:
31568231
7.

Membranous Nephropathy Post-Transplantation: An Update of the Pathophysiology and Management.

Leon J, Pérez-Sáez MJ, Batal I, Beck LH Jr, Rennke HG, Canaud G, Legendre C, Pascual J, Riella LV.

Transplantation. 2019 Apr 10. doi: 10.1097/TP.0000000000002758. [Epub ahead of print]

PMID:
30985736
8.

Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.

Zaghrini C, Seitz-Polski B, Justino J, Dolla G, Payré C, Jourde-Chiche N, Van de Logt AE, Booth C, Rigby E, Lonnbro-Widgren J, Nystrom J, Mariat C, Cui Z, Wetzels JFM, Ghiggeri G, Beck LH Jr, Ronco P, Debiec H, Lambeau G.

Kidney Int. 2019 Mar;95(3):666-679. doi: 10.1016/j.kint.2018.10.024.

PMID:
30784662
9.

Structure and function insights garnered from in silico modeling of the thrombospondin type-1 domain-containing 7A antigen.

Stoddard SV, Welsh CL, Palopoli MM, Stoddard SD, Aramandla MP, Patel RM, Ma H, Beck LH Jr.

Proteins. 2019 Feb;87(2):136-145. doi: 10.1002/prot.25640. Epub 2018 Dec 21.

10.

Deep pockets are not necessarily a good thing in membranous nephropathy: evidence for a modifier allele.

Beck LH Jr, Salant DJ.

Kidney Int. 2018 Nov;94(5):855-857. doi: 10.1016/j.kint.2018.07.010.

PMID:
30348302
11.

Alternative Pathway Is Essential for Glomerular Complement Activation and Proteinuria in a Mouse Model of Membranous Nephropathy.

Luo W, Olaru F, Miner JH, Beck LH Jr, van der Vlag J, Thurman JM, Borza DB.

Front Immunol. 2018 Jun 22;9:1433. doi: 10.3389/fimmu.2018.01433. eCollection 2018.

12.

Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy.

Al-Rabadi L, Quillen K, Shashar M, Al Marji C, Jaberi A, Chitalia V, Henderson J, Salant D, Beck LH Jr.

Kidney Int Rep. 2017 Aug 19;3(2):476-481. doi: 10.1016/j.ekir.2017.08.005. eCollection 2018 Mar. No abstract available.

13.

Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.

Malatesta-Muncher R, Eldin KW, Beck LH Jr, Michael M.

Pediatr Nephrol. 2018 Jun;33(6):1089-1092. doi: 10.1007/s00467-018-3923-5. Epub 2018 Mar 15.

PMID:
29546599
14.

LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease.

Larsen CP, Trivin-Avillach C, Coles P, Collins AB, Merchant M, Ma H, Wilkey DW, Ambruzs JM, Messias NC, Cossey LN, Rosales IA, Wooldridge T, Walker PD, Colvin RB, Klein J, Salant DJ, Beck LH Jr.

J Am Soc Nephrol. 2018 Feb;29(2):644-653. doi: 10.1681/ASN.2017060664. Epub 2017 Oct 26.

15.

PLA2R and THSD7A: Disparate Paths to the Same Disease?

Beck LH Jr.

J Am Soc Nephrol. 2017 Sep;28(9):2579-2589. doi: 10.1681/ASN.2017020178. Epub 2017 Jul 3. Review.

16.

Detection and monitoring PLA2R autoantibodies by LIPS in membranous nephropathy.

Burbelo PD, Beck LH Jr, Waldman M.

J Immunol Methods. 2017 May;444:17-23. doi: 10.1016/j.jim.2017.02.001. Epub 2017 Feb 4.

17.

Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab.

Waldman M, Beck LH Jr, Braun M, Wilkins K, Balow JE, Austin HA 3rd.

Kidney Int Rep. 2016 Jul;1(2):73-84. Epub 2016 Jun 11.

18.

An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy.

Hoxha E, Beck LH Jr, Wiech T, Tomas NM, Probst C, Mindorf S, Meyer-Schwesinger C, Zahner G, Stahl PR, Schöpper R, Panzer U, Harendza S, Helmchen U, Salant DJ, Stahl RA.

J Am Soc Nephrol. 2017 Feb;28(2):520-531. doi: 10.1681/ASN.2016010050. Epub 2016 Jul 19.

19.

Membranous Nephropathy: A Journey From Bench to Bedside.

Francis JM, Beck LH Jr, Salant DJ.

Am J Kidney Dis. 2016 Jul;68(1):138-47. doi: 10.1053/j.ajkd.2016.01.030. Epub 2016 Apr 13. Review.

20.

Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation.

Gupta G, Fattah H, Ayalon R, Kidd J, Gehr T, Quintana LF, Kimball P, Sadruddin S, Massey HD, Kumar D, King AL, Beck LH Jr.

Clin Transplant. 2016 Apr;30(4):461-9. doi: 10.1111/ctr.12711. Epub 2016 Mar 11.

PMID:
26854647
21.

THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity.

Larsen CP, Cossey LN, Beck LH.

Mod Pathol. 2016 Apr;29(4):421-6. doi: 10.1038/modpathol.2016.32. Epub 2016 Feb 5.

22.

Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report.

Al-Rabadi L, Ayalon R, Bonegio RG, Ballard JE, Fujii AM, Henderson JM, Salant DJ, Beck LH Jr.

Am J Kidney Dis. 2016 May;67(5):775-8. doi: 10.1053/j.ajkd.2015.10.031. Epub 2015 Dec 29.

23.

Recurrent Membranous Nephropathy After Kidney Transplantation: Treatment and Long-Term Implications.

Grupper A, Cornell LD, Fervenza FC, Beck LH Jr, Lorenz E, Cosio FG.

Transplantation. 2016 Dec;100(12):2710-2716. doi: 10.1097/TP.0000000000001056. Epub 2015 Dec 30.

PMID:
26720301
24.

Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction?

Abudayyeh A, Truong LD, Beck LH Jr, Weber DM, Rezvani K, Abdelrahim M.

Clin Kidney J. 2015 Aug;8(4):440-4. doi: 10.1093/ckj/sfv036. Epub 2015 Jun 1.

25.

Anti-phospholipase A₂ receptor antibodies in recurrent membranous nephropathy.

Kattah A, Ayalon R, Beck LH Jr, Sethi S, Sandor DG, Cosio FG, Gandhi MJ, Lorenz EC, Salant DJ, Fervenza FC.

Am J Transplant. 2015 May;15(5):1349-59. doi: 10.1111/ajt.13133. Epub 2015 Mar 12.

26.
27.

Recurrent glomerular disease in the kidney allograft.

Menn-Josephy H, Beck LH Jr.

Front Biosci (Elite Ed). 2015 Jan 1;7:135-48. Review.

PMID:
25553369
28.

Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.

Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RAK, Lambeau G.

N Engl J Med. 2014 Dec 11;371(24):2277-2287. doi: 10.1056/NEJMoa1409354. Epub 2014 Nov 13.

29.

The dominant humoral epitope in phospholipase A2 receptor-1: presentation matters when serving up a slice of π.

Beck LH Jr.

J Am Soc Nephrol. 2015 Feb;26(2):237-9. doi: 10.1681/ASN.2014090877. Epub 2014 Oct 6. No abstract available.

30.

Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study.

Timmermans SA, Damoiseaux JG, Heerings-Rewinkel PT, Ayalon R, Beck LH Jr, Schlumberger W, Salant DJ, van Paassen P, Tervaert JW; Limburg Renal Registry.

Am J Clin Pathol. 2014 Jul;142(1):29-34. doi: 10.1309/AJCP8QMOY5GLRSFP.

PMID:
24926082
31.

Membranous nephropathy: from models to man.

Beck LH Jr, Salant DJ.

J Clin Invest. 2014 Jun;124(6):2307-14. doi: 10.1172/JCI72270. Epub 2014 Jun 2. Review.

32.

Antiphospholipase A₂ receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy.

Behnert A, Schiffer M, Müller-Deile J, Beck LH Jr, Mahler M, Fritzler MJ.

J Immunol Res. 2014;2014:143274. doi: 10.1155/2014/143274. Epub 2014 Apr 9.

33.

A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.

Hladunewich MA, Cattran D, Beck LH, Odutayo A, Sethi S, Ayalon R, Leung N, Reich H, Fervenza FC.

Nephrol Dial Transplant. 2014 Aug;29(8):1570-7. doi: 10.1093/ndt/gfu069. Epub 2014 Apr 8.

34.

Membranous nephropathy: not just a disease for adults.

Ayalon R, Beck LH Jr.

Pediatr Nephrol. 2015 Jan;30(1):31-9. doi: 10.1007/s00467-013-2717-z. Epub 2013 Dec 29. Review.

35.

The role of complement in membranous nephropathy.

Ma H, Sandor DG, Beck LH Jr.

Semin Nephrol. 2013 Nov;33(6):531-42. doi: 10.1016/j.semnephrol.2013.08.004. Review.

36.

Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy.

Timmermans SA, Ayalon R, van Paassen P, Beck LH Jr, van Rie H, Wirtz JJ, Verseput GH, Frenken LA, Salant DJ, Cohen Tervaert JW; Limburg Renal Registry.

Am J Kidney Dis. 2013 Dec;62(6):1223-5. doi: 10.1053/j.ajkd.2013.07.019. Epub 2013 Sep 8. No abstract available.

PMID:
24021909
37.

Mouse models of membranous nephropathy: the road less travelled by.

Borza DB, Zhang JJ, Beck LH Jr, Meyer-Schwesinger C, Luo W.

Am J Clin Exp Immunol. 2013 Jun 15;2(2):135-45. Print 2013.

38.

Monoclonal anti-PLA2R and recurrent membranous nephropathy: another piece of the puzzle.

Beck LH Jr.

J Am Soc Nephrol. 2012 Dec;23(12):1911-3. doi: 10.1681/ASN.2012101023. Epub 2012 Nov 8. No abstract available.

39.

Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.

Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, Dillon JJ, Nachman PH, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC.

Nephrol Dial Transplant. 2013 Jan;28(1):137-46. doi: 10.1093/ndt/gfs379. Epub 2012 Sep 17.

40.

Coexistence of ANCA-associated glomerulonephritis and anti-phospholipase A(2) receptor antibody-positive membranous nephropathy.

Surindran S, Ayalon R, Hasan N, Beck LH Jr, Salant DJ, Barisoni L, Skolnik EY, Beara-Lasic L.

Clin Kidney J. 2012 Apr;5(2):162-165. Epub 2012 Mar 9.

41.

Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.

Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB.

Am J Nephrol. 2012;36(1):58-67. doi: 10.1159/000339287. Epub 2012 Jun 19.

PMID:
22722778
42.

IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor.

Khosroshahi A, Ayalon R, Beck LH Jr, Salant DJ, Bloch DB, Stone JH.

Int J Rheumatol. 2012;2012:139409. doi: 10.1155/2012/139409. Epub 2012 May 10.

43.

Monoclonal antibodies for the treatment of the C3 glomerulopathies.

Beck LH Jr.

Clin J Am Soc Nephrol. 2012 May;7(5):704-6. doi: 10.2215/CJN.03010312. Epub 2012 Apr 12. No abstract available.

44.

Very early recurrence of anti-Phospholipase A2 receptor-positive membranous nephropathy after transplantation.

Blosser CD, Ayalon R, Nair R, Thomas C, Beck LH Jr.

Am J Transplant. 2012 Jun;12(6):1637-42. doi: 10.1111/j.1600-6143.2011.03957.x. Epub 2012 Mar 5.

45.

Childhood membranous nephropathy and dietary antigens.

Beck LH Jr.

Am J Kidney Dis. 2012 Feb;59(2):174-6. doi: 10.1053/j.ajkd.2011.09.009. Epub 2011 Oct 20. No abstract available.

PMID:
22014402
46.

Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.

Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ.

J Am Soc Nephrol. 2011 Aug;22(8):1543-50. doi: 10.1681/ASN.2010111125. Epub 2011 Jul 22.

47.

IgG4-related tubulointerstitial nephritis with membranous nephropathy.

Fervenza FC, Downer G, Beck LH Jr, Sethi S.

Am J Kidney Dis. 2011 Aug;58(2):320-4. doi: 10.1053/j.ajkd.2011.05.006. Epub 2011 Jun 25.

PMID:
21705127
48.

Membranous nephropathy associated with IgG4-related disease.

Cravedi P, Abbate M, Gagliardini E, Galbusera M, Buelli S, Sabadini E, Marasà M, Beck LH Jr, Salant DJ, Benigni A, D'Agati V, Remuzzi G.

Am J Kidney Dis. 2011 Aug;58(2):272-5. doi: 10.1053/j.ajkd.2011.05.002. Epub 2011 Jun 12.

PMID:
21658826
49.

Anti-phospholipase A2 receptor antibody in membranous nephropathy.

Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z.

J Am Soc Nephrol. 2011 Jun;22(6):1137-43. doi: 10.1681/ASN.2010090967. Epub 2011 May 12.

50.

Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.

Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1286-91. doi: 10.2215/CJN.07210810. Epub 2011 Apr 7.

Supplemental Content

Support Center